Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adjuvant radiation therapy trends and predictors in Merkel cell carcinoma, a 20-year SEER analysis.

Journal of the American Academy of Dermatology·2026
Same author

A Dermatologist's Perspective on Cutaneous Adverse Effects in CTCAE Version 6.0.

JAMA oncology·2026
Same author

Pregnancy and risk of melanoma: a matched retrospective cohort study.

Melanoma research·2026
Same author

Reassessing Treatment Outcomes Following Immune-Related Adverse Events-Reply.

JAMA oncology·2026
Same author

Inpatient initiation of long-acting injectable buprenorphine for adolescents and young adults with opioid use disorder.

Journal of substance use and addiction treatment·2026
Same author

Lipoprotein(a) and incident venous thromboembolism in pre- and postmenopausal women, and in men.

European heart journal·2026

Related Experiment Video

Updated: Sep 19, 2025

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.2K

Tape Strip Profiling of Checkpoint Inhibitor-Associated Dermatitis Highlights Pan-T-Cell Activation: A Pilot Study.

Camille M Powers1, Madeline Kim1, Annie Chang1

  • 1Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

JID Innovations : Skin Science From Molecules to Population Health
|June 16, 2025
PubMed
Summary

Immune checkpoint inhibitor (ICI) skin toxicities show distinct molecular patterns compared to atopic dermatitis. This research identifies unique immune pathways in ICI-associated dermatitis and lichen planus, offering potential therapeutic targets.

Keywords:
Atopic dermatitisCutaneous immune-related adverse eventsOncodermatologyRNA sequencingTape strips

More Related Videos

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.8K
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.3K

Related Experiment Videos

Last Updated: Sep 19, 2025

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.2K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.8K
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.3K

Area of Science:

  • Immunology
  • Dermatology
  • Oncology

Background:

  • Immune checkpoint inhibitors (ICIs) are crucial cancer therapies but can cause non-tumor tissue adverse effects.
  • Cutaneous immune-related adverse events (irAEs) are common ICI toxicities with unclear mechanisms.
  • Understanding these skin reactions is vital for patient management without compromising anti-cancer treatment.

Purpose of the Study:

  • To investigate the molecular phenotype of ICI-associated eczematous dermatitis and lichen planus.
  • To compare these conditions with atopic dermatitis and healthy controls using transcriptomic analysis.
  • To identify distinct immune pathways in cutaneous irAEs for potential therapeutic targeting.

Main Methods:

  • Pilot study utilizing minimally invasive tape strip sampling.
  • Transcriptomic analysis of lesional and nonlesional skin.
  • Comparison between ICI-associated conditions, atopic dermatitis, and healthy controls.

Main Results:

  • Significant T helper 1 upregulation observed in lesional ICI-associated eczematous dermatitis and lichen planus, exceeding that in atopic dermatitis.
  • Elevated T helper 2 markers, including IL4R, noted in both ICI subtypes.
  • Unique JAK3 modulation identified in lesional ICI-associated eczematous dermatitis.
  • Broad immune dysregulation found in both lesional and nonlesional ICI-associated lichen planus.

Conclusions:

  • Cutaneous irAEs exhibit distinct immune pathway alterations compared to ICI-independent dermatoses.
  • Findings suggest potential early inflammation in nonlesional skin of ICI-associated lichen planus.
  • Identified pathways may represent novel therapeutic targets for managing irAEs while preserving ICI efficacy.